Agilent Technologies (NYSE:A) Issues Q4 2026 Earnings Guidance

Key Points

• Agilent Technologies issued Q4 2026 EPS guidance of $1.71–$1.74, in line with the $1.71 analyst consensus, while revenue guidance was approximately $2.0 billion. Full-year 2026 EPS guidance was set at $6.18–$6.21.
• The company’s latest quarterly results exceeded expectations, with EPS of $1.62 versus the $1.49 consensus and revenue of $1.88 billion versus estimates of $1.84 billion.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and a $160.24 target price. Shares recently traded at $155.16, near their 52-week high of $160.51.

Agilent Technologies (NYSE:A - Get Free Report) issued an update on its fourth quarter 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.710-1.740 for the period, compared to the consensus estimate of 1.710. The company issued revenue guidance of $2.0 billion-$2.0 billion, compared to the consensus revenue estimate of $2.0 billion. Agilent Technologies also updated its FY 2026 guidance to 6.180-6.210 EPS.

Wall Street Analysts Forecast Growth

A has been the topic of a number of recent research reports. Piper Sandler assumed coverage on Agilent Technologies in a research note on Thursday, June 11th. They set a "neutral" rating and a $150.00 target price on the stock. Wolfe Research reaffirmed a "hold" rating on shares of Agilent Technologies in a report on Tuesday, June 2nd. TD Cowen increased their price objective on Agilent Technologies from $147.00 to $155.00 and gave the stock a "buy" rating in a research report on Thursday, May 28th. Barclays lifted their target price on Agilent Technologies from $145.00 to $150.00 and gave the stock an "overweight" rating in a report on Wednesday, June 24th. Finally, Robert W. Baird boosted their target price on shares of Agilent Technologies from $155.00 to $156.00 and gave the company an "outperform" rating in a research report on Tuesday, May 26th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $160.24.

Agilent Technologies Price Performance

Shares of A stock traded up $0.39 during trading on Wednesday, hitting $155.16. The company had a trading volume of 3,131,622 shares, compared to its average volume of 2,234,282. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.62 and a current ratio of 2.10. The firm has a market capitalization of $43.82 billion, a P/E ratio of 31.16, a price-to-earnings-growth ratio of 2.71 and a beta of 1.25. The stock's 50-day moving average price is $138.55 and its 200 day moving average price is $126.47. Agilent Technologies has a one year low of $108.35 and a one year high of $160.51.

Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings data on Wednesday, August 26th. The medical research company reported $1.62 EPS for the quarter, topping analysts' consensus estimates of $1.49 by $0.13. The firm had revenue of $1.88 billion for the quarter, compared to analyst estimates of $1.84 billion. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. Equities analysts expect that Agilent Technologies will post 6.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Agilent Technologies

Institutional investors and hedge funds have recently bought and sold shares of the company. Compound Planning Inc. boosted its stake in shares of Agilent Technologies by 47.8% in the 4th quarter. Compound Planning Inc. now owns 3,705 shares of the medical research company's stock valued at $504,000 after purchasing an additional 1,199 shares during the last quarter. Invesco Ltd. boosted its position in Agilent Technologies by 32.0% during the fourth quarter. Invesco Ltd. now owns 2,590,715 shares of the medical research company's stock valued at $352,519,000 after acquiring an additional 627,804 shares during the last quarter. Corient Private Wealth LLC boosted its position in Agilent Technologies by 53.7% during the fourth quarter. Corient Private Wealth LLC now owns 284,303 shares of the medical research company's stock valued at $38,685,000 after acquiring an additional 99,385 shares during the last quarter. Mercer Global Advisors Inc. ADV grew its holdings in Agilent Technologies by 1.9% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 60,542 shares of the medical research company's stock worth $8,238,000 after acquiring an additional 1,131 shares during the period. Finally, Vident Advisory LLC raised its position in shares of Agilent Technologies by 4.7% in the 4th quarter. Vident Advisory LLC now owns 17,052 shares of the medical research company's stock worth $2,320,000 after acquiring an additional 765 shares in the last quarter.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source